US Pharma MarketingKura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential
Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with the KRAS inhibitor.
Source: FierceBiotech